23 months now, here’s why
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__13. Undisclosed Antimetabolite ANDA- $42 Million
__14. $50 million in yearly revenues
__15. Generate revenues over $20 million/quarter
__16. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__17. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 18. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__19. European distribution - Dexcel partnership approval by Israeli Health
__20. Full ownership of Adderall IR $ 335 Million
__21. Full ownership of Adderall XR $ 1.56 Billion
__22. Generic Concerta- $1.2 BILLION FDA submission
__23. Vigabatrin - APPROVED - VigPoder Pyros $233 Million trade mark challenge
__24. $100 million in yearly revenues
__25. Patented Unique ADF (w/o naltrexone)-- NDA
__26. Mikah ANDA (s)
__27. Undisclosed ANDAs/NDAs
__28. Antimetabolite ANDA- Methotrexate -$600 Million - unconfirmed
__29. Generic Vyvanse Approval
__30. DollarLand PPS
__31. Uplist to the NASDAQ Exchange
__32. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__33. Vegas Baby !!!!!!!
X 34. PE ratio below 8.0
